Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 May;42(1):42-51.
doi: 10.1097/01.qai.0000219771.97303.0a.

A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART

Carol E Golin  1 , Joanne Earp, Hsiao-Chuan Tien, Paul Stewart, Carol Porter, Lynn Howie
Affiliations
Clinical Trial

A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART

Carol E Golin et al. J Acquir Immune Defic Syndr. 2006 May.

Abstract

Rationale and purpose: Motivational interviewing (MI) is a counseling technique that has been used effectively to change a number of health-related behaviors. We sought to assess the impact on patients' antiretroviral therapy (ART) adherence of a multicomponent, MI-based ART adherence intervention compared with that of an HIV informational control program.

Study design: Two-arm, randomized, controlled trial.

Sample: One hundred forty adult HIV-infected patients attending a large, academic center infectious diseases clinic who were either failing or newly initiating an ART regimen. STUDY ENDPOINTS: (1) Mean adherence level (% of prescribed doses take in the prior month) at the week 12 visit, (2) change in mean adherence, (3) percentage of patients achieving >95% adherence in the third 4-week block, and (4) change in viral load.

Main findings: The MI group's mean adherence improved by 4.5% compared with a decrease in the control group's adherence by 3.83% (P = 0.10). In the treatment group, 29% achieved >95% adherence compared with only 17% in the control group (P = 0.13). When we controlled for ethnicity, the intervention group had 2.75 times higher odds of achieving more than 95% adherence than did the controls (P = 0.045; 95% confidence interval: 1.023, 7.398). Although a number of mediating variables (beliefs about ART, coping style, social support, and goals set) had statistically significant changes in the expected direction in the MI group compared with controls, in the intent-to-treat analysis, the mean adherence at study exit for the intervention group was 76% (SD = 27%) and 71% (SD = 27%) for the control group (P = 0.62).

Conclusion: Although not definitive, this study provides some evidence that MI offers an effective approach to improving adherence. Future studies able to build MI into the intervention for longer than 3 months may have a greater impact.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Study design.
FIGURE 2
FIGURE 2
Recruitment and retention patterns of study participants.
FIGURE 3
FIGURE 3
Mean of eDEMs from weeks 1 to 12 by treatment group.
See this image and copyright information in PMC

References

    1. Liu HH, Golin CG, Miller L, et al. A comparison of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968–977. - PubMed
    1. Fogarty L, Roter D, Larson S, et al. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46(2):93–108. - PubMed
    1. Altice F, Friedland G. The era of adherence to HIV therapy. Ann Intern Med. 1998;129(6):503–505. - PubMed
    1. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV resistance. JAMA. 1998;279(24):1977–1983. - PubMed
    1. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–366. - PubMed

Publication types

Substances